NitroMed acquires BiDil (isosorbide dinitrate/hydralazine) NDA and related intellectual property from Jay Cohn, MD, University of Minnesota, who will retain royalty rights. Medco filed the BiDil NDA for reduction of mortality and treatment of congestive heart failure in July 1996, but returned the rights to Cohn in 1998. NitroMed plans to amend the existing NDA to seek an indication for treatment of CHF in African-American patients, based on new data showing that the mortality of black patients receiving hydrazaline plus isosorbide dinitrate was reduced, the company said
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth